{
    "root": "2f1fa6e7-20a7-47c5-a8fe-6ade26ea89c8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Rosuvastatin",
    "value": "20250203",
    "ingredients": [
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "SODIUM BICARBONATE",
            "code": "8MDF5V39QO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01390"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "ROSUVASTATIN CALCIUM",
            "code": "83MVU38M7Q",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77249"
        }
    ],
    "indications": {
        "text": "rosuvastatin tablets indicated : \u2022 reduce risk major cardiovascular ( cv ) events ( cv death , nonfatal myocardial infarction , nonfatal stroke , arterial revascularization procedure ) adults without established coronary heart disease increased risk cv disease based age , high-sensitivity c-reactive protein ( hscrp ) \u22652 mg/l , least one additional cv risk factor . \u2022 adjunct diet : reduce low-density lipoprotein cholesterol ( ldl-c ) adults primary hyperlipidemia . reduce ldl-c slow progression atherosclerosis adults . reduce ldl-c adults pediatric patients aged 8 years older heterozygous familial hypercholesterolemia ( hefh ) . \u2022 adjunct ldl-c-lowering therapies , alone treatments unavailable , reduce ldl-c adults pediatric patients aged 7 years older homozygous familial hypercholesterolemia ( hofh ) . \u2022 adjunct diet treatment adults : primary dysbetalipoproteinemia . hypertriglyceridemia .",
        "doid_entities": [
            {
                "text": "myocardial infarction (DOID:5844)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5844"
            },
            {
                "text": "stroke (DOID:6713)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6713"
            },
            {
                "text": "coronary heart disease (DOID:3393)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3393"
            },
            {
                "text": "heart disease (DOID:114)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_114"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "atherosclerosis (DOID:1936)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1936"
            },
            {
                "text": "familial hypercholesterolemia (DOID:13810)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13810"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "take orally without food , time day . ( 2.1 ) assess ldl-c clinically appropriate , early 4 weeks initiating rosuvastatin tablets , adjust necessary . ( 2.1 ) adults : recommended range 5 40 mg daily . ( 2.1 ) pediatric patients hefh : recommended range 5 10 mg daily patients aged 8 less 10 years age , 5 20 mg daily patients aged 10 years older . ( 2.2 ) pediatric patients hofh : recommended 20 mg daily patients aged 7 years older . ( 2.2 ) asian patients : initiate 5 mg daily . consider risks benefits treatment adequately controlled doses 20 mg daily . ( 2.4 ) patients severe renal impairment ( hemodialysis ) : initiate 5 mg daily ; exceed 10 mg daily . ( 2.5 ) full prescribing information rosuvastatin modifications due . ( 2.6 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "rosuvastatin tablets usp supplied : 20 mg : light pink pink , round , bevel edged biconvex film coated tablets , debossed ' h ' one side 'r5 ' side . ndc 71335-9669-1 : 30 tablets bottle ndc 71335-9669-2 : 90 tablets bottle ndc 71335-9669-3 : 28 tablets bottle ndc 71335-9669-4 : 60 tablets bottle ndc 71335-9669-5 : 180 tablets bottle ndc 71335-9669-6 : 120 tablets bottle storagestore 20\u00ba 25\u00bac ( 68\u00ba 77\u00baf ) [ usp controlled room temperature ] . protect moisture . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "rosuvastatin contraindicated following conditions : \u2022 acute liver failure decompensated cirrhosis [ ( 5.3 ) ] . \u2022 hypersensitivity rosuvastatin excipients rosuvastatin . hypersensitivity including rash , pruritus , urticaria , angioedema reported rosuvastatin [ ( 6.1 ) ] .",
    "indications_original": "Rosuvastatin tablets are indicated: \n    \u2022\u00a0To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) \u22652 mg/L, and at least one additional CV risk factor.\u00a0 \n    \u2022\u00a0As an adjunct to diet to: \n    \u00a0 \u00a0 \u00a0 o\u00a0Reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia. \n    \u00a0 \u00a0 \u00a0 o\u00a0Reduce LDL-C and slow the progression of atherosclerosis in adults. \n    \u00a0 \u00a0 \u00a0 o\u00a0Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). \n    \u2022\u00a0As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). \n    \u2022\u00a0As an adjunct to diet for the treatment of adults with: \n    \u00a0 \u00a0 \u00a0 o\u00a0Primary dysbetalipoproteinemia. \n    \u00a0 \u00a0 \u00a0 o\u00a0Hypertriglyceridemia.",
    "contraindications_original": "Take orally with or without food, at any time of day. ( 2.1 ) Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating\u00a0 rosuvastatin tablets, and adjust dosage if necessary. ( 2.1 ) Adults: Recommended dosage range is 5 to 40 mg once daily. ( 2.1 ) Pediatric Patients with HeFH: Recommended dosage range is 5 to 10 mg once daily for patients aged 8 to less than 10 years of age, and 5 to 20 mg once daily for patients aged 10 years and older. ( 2.2 ) Pediatric Patients with HoFH: Recommended dosage is 20 mg once daily for patients aged 7 years and older. ( 2.2 ) Asian Patients: Initiate at 5 mg once daily. Consider risks and benefits of treatment if not adequately controlled at doses up to 20 mg once daily. ( 2.4 ) Patients with Severe Renal Impairment (not on hemodialysis): Initiate at 5 mg once daily; do not exceed 10 mg once daily. ( 2.5 ) See full prescribing information for rosuvastatin dosage and administration modifications due to drug interactions. ( 2.6 )",
    "warningsAndPrecautions_original": "Rosuvastatin Tablets USP are supplied as:\n                  20 mg: Light pink to pink, round, bevel edged biconvex film coated tablets, debossed with 'H' on one side and 'R5' on the other side.\n                  \n                     NDC 71335-9669-1: 30 Tablets in a BOTTLE\n                     NDC 71335-9669-2: 90 Tablets in a BOTTLE\n                     NDC 71335-9669-3: 28 Tablets in a BOTTLE\n                     NDC 71335-9669-4: 60 Tablets in a BOTTLE\n                     NDC 71335-9669-5: 180 Tablets in a BOTTLE\n                     NDC 71335-9669-6: 120 Tablets in a BOTTLE\n                  \n                  StorageStore at 20\u00ba to 25\u00baC (68\u00ba to 77\u00baF) [see USP Controlled Room Temperature]. Protect from moisture.\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Rosuvastatin is contraindicated in the following conditions: \n    \u2022 Acute liver failure or decompensated cirrhosis\n \n  [see\u00a0\n  \n   Warnings and Precautions (5.3)].\n \n  \n                       \u2022 Hypersensitivity to rosuvastatin or any excipients in rosuvastatin. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with rosuvastatin\n \n  [see\n  \n   Adverse Reactions (6.1)].",
    "drug": [
        {
            "name": "Rosuvastatin",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_38545"
        }
    ]
}